Accelerate the adoption of your therapy.
We develop and implement evidence-based strategies to overcome barriers to adoption of new therapies within health systems and disease pathways.
Speak to our expertsIllustration of a two-tone capsule inside an orbit ring with three nodes, above a heartbeat line.
Trusted by
The challenge
1 in 2 new drug launches fail to meet forecasts. Even blockbuster drugs don't reach their full potential. That's the gap we help close.
Our solution: Adoption Excellence
Prova Health's work with pharma companies focuses on Adoption Excellence: helping therapies reach more patients through strategies that don't stop at launch. We help identify barriers to adoption, develop strategies to address them and support their implementation. Our Adoption Excellence approach includes the following elements
Diagnostic
Predict what barriers are likely to limit adoption of your therapy in key markets and quantify their potential impact.
Activities
- Analysis of adoption barriers across the disease pathway and by population sub-groups
- Comparative analysis across markets
- Sizing of adoption barriers (e.g., number of patients, sales volume)
- Clinical expert validation
Strategy
Identify, prioritise and design interventions to address adoption barriers, tailored to the realities of each market and health system.
Activities
- Horizon scanning to identify relevant case studies
- Cost, resource and impact modelling of each intervention
- Value proposition development
- Clinical expert validation
Implementation and capability building
Address adoption barriers by successfully implementing priority interventions, equipping teams with the right skills to do so.
Activities
- Capability building
- Development of implementation toolkits
- Development of materials to engage providers
- Coordination of global and country efforts
Why Prova Health
Proprietary adoption intelligence
50+ disease pathway maps and 20+ health system profiles. Rapid assessment of adoption barriers specific to your therapy.
Global clinical expert network
600+ healthcare insiders from 40+ countries in the proprietary Prova Health Network. 10× faster access to clinicians and experts to generate and validate insights.
Real world data and health economics
Deep quantitative capability to model investment, impact and value of adoption barriers and interventions to address them.
Case studies
View all case studiesSupporting the launch of a new indication for a breast cancer drug in four countries
Generate insights and data to support the launch of a new breast cancer drug in Germany, Italy, Canada, and Switzerland.
Read the case study: Supporting the launch of a new indication for a breast cancer drug in four countriesDriving adoption of best practice clinical protocols for cardiovascular disease in Japan
Address the uneven adoption of best practice clinical guidelines and protocols in atherosclerotic cardiovascular disease across Japan.
Read more: Driving adoption of best practice clinical protocols for cardiovascular disease in JapanCreating a global healthcare system academy for a top-10 pharmaceutical company
Provide the most senior executives in the company’s most important markets with the knowledge and skills to develop new partnerships within their health system.
Read more: Creating a global healthcare system academy for a top-10 pharmaceutical company
Frequently asked questions
By truly understanding their customers and the realities in which they operate. Pharma companies often overlook the importance of having an in-depth understanding of the health systems and clinical pathways in which their therapies need to integrate. The evidence shows that this has led to disappointing launches, missed sales targets and material impact on patients reached and potential share price. Effective adoption optimisation strategies can significantly impact a therapy's success.
We help pharma companies understand and shape clinical, operational and health system realities. Through our proprietary intelligence, global network and expertise we generate essential insights to address barriers to adoption and maximise the success of launches and commercial strategies. We train pharma leaders at the global and country levels to use those insights effectively and maximise chances of success.
For over 40 diseases, we have mapped the end to end pathway at the health system, rather than individual patient, level. Our analysis covers the key steps of the pathway, indicators of performance and likely barriers to the adoption of new therapies. It can provide you with an early understanding of what could limit the potential of your innovation.
We work with a variety of teams in pharma companies, usually within the commercial, market access or medical affairs organisations, at global or country level. The name and organisational structure of the teams that focus on adoption vary widely across companies. We have worked with teams called, for example, "Population Health", "Health System Partnerships", "Health Equity".
In both pharma and digital health/AI our focus is on accelerating the adoption of innovation. The fact that we work across both innovation types is an added value for our clients. Digital health innovators benefit from our deep understanding of pharma as they consider go-to-market strategies and partnerships. Pharma companies benefit from our digital health expertise as they seek innovative ways to drive adoption of their therapies.